Summary Lymph node status is still the single most important prognostic factor in breast cancer. Axillary surgery remains the only reliable means of providing this information. This pilot study evaluates using a highly specific radiolabelled monoclonal antibody to provide equivalent infornation by a non-invasive technique.
Radioimmunolocalisation, the use of radiolabelled monoclonal antibodies to localise tumour deposits displaying the target antigen, has been used in the staging of breast cancer with varied results (Tjandra et al., 1989a,b; Athanassiou et al., 1988) . Successful localisation of an antibody to the target antigen relies firstly on there being a high level of antigen expression by the tumour relative to normal tissues (Weinstein et al., 1984; Vaickus & Foon, 1991) and secondly, the availability of highly specific antibodies which recognise the target antigen. This tumour specificity is itself an essential prerequisite to any future development of immunotherapeutic applications (Bradwell et al., 1985; Schlom, 1989) . Most previously reported studies have used a single monoclonal antibody of moderate specificity for a tumour to investigate the potential for staging all cases of that cancer type under investigation (Thompson et al., 1984; Yiu et al., 1991) , without making allowance for heterogeneity of antigen expression either between different tumour deposits or within a tumour itself. In addition, the level of antigen expression in many tumours is not signficantly elevated above that found on normal tissues, thus making successful tumour localisation unlikely.
We have tried to circumvent these problems of variable antigen expression by using a panel of monoclonal antibodies that are highly specific to clearly defined, but not universally expressed, cell surface antigens. By selecting the antibody for radioimmunolocalisation studies on the basis of prior immunostaining of fine needle aspirates of each tumour we aimed to identify the best antibody to be used for the investigation of each individual patient. We present the results from the first of our antibodies, ICR12 (Styles et al., 1990) that has been fully evaluated both in vitro, in vivo and in clinical cases. This antibody, which is a rat IgG2a monoclonal, is directed against the extracellular domain of the 185 kDa product of the c-erbB-2 proto-oncogene; a transmembrane tyrosine kinase related to the receptor for epidermal growth factor. Amplification of this gene and overexpression of the product has been found in some 20% of breast cancers and overexpression has been found to correlate with poor prognosis in these patients (Slamon et al., 1987; Gusterson et al., 1988) . The minimal levels of expression of this antigen in most normal tissues make this a highly tumour specific target (Perren, 1992) . ICR12 was selected from a panel of rat monoclonal antibodies to p185 on the basis that it binds both to frozen and formalin fixed paraffin embedded tumour sections that overexpress p185 and it will localise with high efficiency and stability to p185 expressing breast and ovarian xenografts in athymic mice (Fernando et al., 1992b) (Figure  1 ) and the results obtained with the cytospin samples were verified by staining of fixed paraffin embedded tissue obtained from the surgically resected specimen (Fernando et al., 1992b Radiolabelling procedure After consideration of previous studies with differing isotopes and differing labelling methods including chelation methods of labelling with Tc99m, Technetium-99m was selected as the radioisotope for use with a reduction method of labelling because of the short half life, excellent imaging characteristics and ease of radiolabelling. ICR12 is labelled with Tc99m using a modification of the Mercaptoethanol reduction method (Schwarz & Steinstraesser, 1987; Mather & Ellison, 1990) . Initial tests showed that the optimal labelling conditions for ICR12 with minimal affect on antibody binding required a modification of the standard technique. Briefly, the optimal conditions were achieved by treatment of the antibody by part reduction with 2-mercaptoethanol (2ME) at a molar ratio of 500 parts 2ME: 1 part antibody, for 30 min at room temperature. The (Millex-GV, Millipore) . This technique of preparation has been tested for sterility and pyrogenicity by accredited commercial quality control testing laboratories.
Labelling efficiency was checked prior to use of each batch of prepared antibody by instant thin layer chromatography.
In the preclinical studies, the effects of differing conditions of radiolabelling on the immunoreactivity of the antibody were established using competitive radioimmunoassay techniques . ICR12 labelled with Tc99m (decayed) was compared with unlabelled ICR12 for its capacity to compete with Iodine-125 labelled ICR12 for binding to the human ovarian carcinoma cell line SKOV3 cells which over expresses the target antigen (Figure 2 ). Standard competitive radioimmunoassay techniques were employed with doubling dilutions of each test antibody against the 1-125-antibody down the cell plate. Further determination of the effect of labelling on immunoreactivity of the radiolabelled antibody was performed by immunoprecipitation studies of Tc99m labelled antibody binding to Sepharose 4B beads coated with an excess of the p185 antigen. The resultant trapping of the active, labelled antibody to the antigen coated beads was measured in an automated gamma counter. This method of testing demonstrates the combined effects of both labelling efficiency and immunoreactivity, rather than testing each function in isolation.
Biodistribution studies in vivo Eight athymic mice bearing established bilateral xenografts of the human breast carcinoma MDA MB-361 tumours were injected intravenously with 100 micrograms of and then killed at 24 h by CO2 asphyxiation. Radioactivity in weighed samples of blood, lungs, liver, spleen, kidneys, muscle, skin and tumours was determined in a gamma well spectrometer and the results expressed in terms of per cent injected dose per gram of tissue (% ID g-').
Imaging technique Patients were given 2 mg of ICR12 labelled with 700 MBq of Tc99m by slow intravenous injection. Axillary and thoracic regions were imaged at 24 h after injection using a General Electric Maxi gamma camera with a standard collimator. Planar acquisition of approximately 200,000 counts was performed initially, followed by 360 degree tomography acquiring in 64 projections for 30 s at each angle. Computerised reconstruction was then undertaken to provide tomographic representations in the transaxial, sagittal and coronal planes. Reconstruction of images was performed using a ramp filter, and these transaxial reconstructions were analysed further by computer to show levels of activity in regions of interest thus quantifying the imaged results. 
Patient studies
To date eight patients have been studied with Tc99m-ICRi2, (Table I) marked homogeneity of the neoplastic cell staining. Radioimmunolocalisation images easily identified the tumour deposits on both planar imaging ( Figure 5 ) as well as the computer enhanced tomographic reconstructions (Figure 6 ). The reconstructed transaxials were then further examined to show region of interest axes and the highlighted tumour deposits showed levels of activity at least three times that of background admixture of blood and normal tissue levels of activity ( Figure 7) . The line axes show activity levels through both breasts along the horizontal axis, while the vertical axis compares the total body mass and blood background against the tumour activity level.
One patient selected for inclusion in the study as a 'positive expresser' of the c-erbB-2 p185 on the basis of staining of the fine needle aspirate failed to localise on radioimmunoscintigraphy with Tc99m-ICR12 (Patient 3). Immunostaining of the surgically resected specimens showed that whilst there was over expression of the gene product on surrounding ductal cancer in situ, the infiltrative component of the tumour which formed the bulk of the tumour mass did not stain. The tandem mouse study showed that the labelled antibody behaved as expected. We concluded that this case represented a problem of sampling by fine needle aspiration rather than a problem with the monoclonal antibody.
Two further patients had only weak to moderate expression of the antigen on their breast cancer cell membranes as shown by pretesting immunostaining. In addition both of these patients had had three or more months of presurgical treatment with Tamoxifen as part of a primary medical treatment programme. Neither of these two patients demonstrated good localisation to either the breast primary or the axillary nodes with Tc99m-ICRI2 radioimmunolocalisation. Whether this was due to the lower degree of antigen expression being displayed by the target tumour, or whether the previous hormonal treatment had in some way modified the immunological target remains to be clarified.
Discussion
Our results from the preclinical evaluation experiments and the subsequent clinical evaluation provide support for the hypothesis that the use of a highly specific antibody against a preselected target will improve the prospects for accurate localisation of tumour deposits by radioimmunolocalisation. The assessment of the efficiency of staining of fine needle aspirates for characterisation of the tumour target has given good agreement with definitive pathological examination and immunocytochemical (Fernando et al., 1992b) although one result (Patient 3) points to the need for careful sampling.
The results of this radioimmunolocalisation study support our hypothesis that in order to improve on previously reported results where a single monoclonal antibody is expected to localise in all cases of a particular tumour type. We recognised that this is asking too much of any individual antibody and have therefore selected antibodies to form a panel from which an antibody is targeted to a specific and predetermined target antigen. By having a panel of highly specific antibodies, from which one is chosen on the basis of testing each individual tumour target antigen expression, the ability of the chosen antibody to recognise that particular individual tumour being tested is therefore established prior to the study. It is in using this method of preselecting antibodies for the task in hand that radioimmunolocalisation will be more likely to provide accurate data for staging purposes. We do however recognise that the extent of the antigen expression and any modifying factors such as pretreatment should be taken into consideration in this selection process.
The results presented in this paper are the initial results of the first antibody from our panel of highly specific antibodies, and show the potential of such a directed means of investigation. The excellent localising properties of ICR12 into tumours that strongly over express c-erbB-2 p 185 and the absence of uptake of this antibody in antigen negative tumours and normal breast tissue suggest that it may have a useful clinical role in staging patients and should be included as a constituent member of our eventual completed panel of antibodies for staging breast cancer.
Recent reports (Wright et al., 1992; Gusterson et al., 1992) suggest that breast cancer patients with tumours that over express the product of the c-erbB-2 proto-oncogenes have a poor prognosis because the tumours are more resistant to chemotherapy or hormonal manipulation. The results of our initial study with ICR12 reported in this paper suggest that the good tumour localising properties of this antibody in those patients that strongly overexpress the target antigen may form a basis for its use in therapeutic applications in these patients, for example in antibody directed prodrug therapy or targeted immunotherapy with either antibody targeted toxins or antibody delivered radiotherapy. In conclusion, not only could ICR12 form part of a panel of antibodies to stage breast cancer and thereby replace axillary surgery as a diagnostic procedure in this condition, but also that the antibody may be of use for delivering and directing subsequent therapeutic management in those patients that strongly over express the c-erbB-2 gene product.
